Comprehensive Analysis of 250+ Key Companies Developing 250+ Novel CAR-T Therapies: DelveInsight
April 20, 2021 20:50 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, April 20, 2021 (GLOBE NEWSWIRE) -- Comprehensive Analysis of 250+ Key Companies Developing 250+ Novel CAR-T Therapies: DelveInsight More than 50% of trials investigating...
Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple Myeloma
December 07, 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, reported...
Teneobio Announces the Presentation of Interim Phase I Data on TNB-383B (Anti-BCMAxCD3) at the 62nd Annual Meeting of the American Society of Hematology
November 19, 2020 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Teneobio Inc., a clinical stage biotech company focused on discovery and development of novel multi-specific biotherapeutic antibodies, today...
Telo Genomics Announces Study Results Showing That TeloView® Differentiates Between Stable Smoldering Multiple Myeloma Patients and Patients That Progressed to Active Multiple Myeloma
November 16, 2020 11:13 ET
|
Telo Genomics Corp.
TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce the positive results of its smoldering multiple myeloma proof of concept...
Cytovia Therapeutics partners with Inserm to develop selective CD38 NK therapeutics and offer new treatment options for Multiple Myeloma patients
October 08, 2020 06:00 ET
|
Cytovia Therapeutics
NEW YORK and PARIS, Oct. 08, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics ("Cytovia"), an emerging biopharmaceutical company, announces today that it has entered a research and licensing agreement...
Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma
September 21, 2020 07:00 ET
|
Precision Biosciences
DURHAM, N.C. and STAMFORD, Conn., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology developing allogeneic CAR T and in vivo gene...
Drs. Kenneth Anderson and Asher Chanan-Khan to Join Starton Therapeutics Board of Directors
September 09, 2020 07:45 ET
|
Starton Therapeutics, Inc.
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company powering continuous delivery of approved drugs in novel...
Sorrento to Present New Data on Advanced Immunotherapies at Multiple Upcoming Scientific Conferences
November 06, 2019 19:37 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, and members of Sorrento’s research team will...
Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma
November 06, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
ChemioCare Strengthens its Proposed Slate of Directors with the Nomination of Multiple Myeloma Expert Dr. Mohamad Hussein
August 29, 2019 07:40 ET
|
ChemioCare
NEW YORK, Aug. 29, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery, announced today the addition of Dr....